|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ligation of the complement regulatory protein CD46 facilitates the differentiation of T helper 1 (T<sub>H</sub>1) effector cells into interleukin-10 (IL-10)-secreting type 1 regulatory T cells (Tr1 cells), and this pathway is defective in MS patients.
|
29066539 |
2017 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Blood samples from untreated patients diagnosed with clinically isolated syndrome (CIS) (<i>n</i> = 21), different clinical forms of MS (<i>n</i> = 62) [relapsing-remitting (RRMS), secondary progressive, and primary progressive], and healthy controls (HCs) (<i>n</i> = 17) were tested for plasma levels of interferon (IFN)-γ, IL-10, TGF-β, IL-17A, and IL-17F by immunoanalysis.
|
28713377 |
2017 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune cells from mouse recipients of MS-twin samples produced less IL-10 than immune cells from mice colonized with healthy-twin samples.
|
28893994 |
2017 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we evaluated whether targeted delivery of MSCs with triple PSGL1/SLeX/IL-10 engineering improves therapeutic outcomes in mouse experimental autoimmune encephalomyelitis (EAE), a murine model for human MS. We found PSGL-1/SLeX mRNA transfection significantly enhanced MSC homing to the inflamed spinal cord.
|
26584349 |
2016 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The levels of TNF-a and IL-10 in the serum and CSF at the relieving stage of MS patients were higher than those of healthy individuals, suggest that at relieving stage, MS may be still developing.
|
27831647 |
2016 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
|
27055778 |
2016 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results showed that: 1) CD19+/TNFα+, CD19+/IL-12+ and CD19+/IFNγ+ lymphocytes are significantly increased in primary progressive (PP) compared to secondary progressive (SP), relapsing-remitting (RR), benign (BE) MS and HC; 2) CD19+/IL-6+ lymphocytes are significantly increased in PP, SP and RR compared to BEMS and HC; and 3) CD19+/IL-13+, CD19+/IL-10+, and CD19+/IL-10+/TGFβ+ (Bregs) B lymphocytes are reduced overall in MS patients compared to HC.
|
27412504 |
2016 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the relationship of stimulated PBMC-produced IFN-γ, TNF-α, IL-4 and IL-10 in modulating relapse risk using a prospective cohort with established relapsing-remitting MS.
|
24790215 |
2015 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increasing evidence indicates that IL-10 plays an important role in both the onset and development of auto-immune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), multiple sclerosis (MS), Crohn's disease (CD), and psoriasis.
|
24639111 |
2014 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This mAb exerted immunosuppressive activity on MS-derived T cell lines through induction and release of high amounts of interleukin-10 and decreased levels of interleukin-12 from activated monocytes providing the biological basis for a potential new treatment for MS and other immune-mediated neurological disorders.
|
23318105 |
2013 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
|
23517930 |
2013 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that endogenous IFN-β may induce the expression of immunoregulatory IL10 in MS and that this might be associated with dampening of inflammatory disease activity.
|
20561040 |
2011 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population.
|
21621860 |
2011 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To study the possible role of tumor necrosis factor-alpha G-308A, interleukin-6 G-174C, interleukin-10 C-592A, C-819T, G-1082A, transforming growth factor (TGF)-beta (codons 10 and 25), and interferon-gamma T+874A polymorphisms in susceptibility to MS in Iranian population, DNA samples from 98 patients and 97 healthy controls were genotyped using polymerase chain reaction-sequence-specific primers.
|
20228669 |
2010 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, the percentage of CD4(+)IL-10(+) Tr1 and suppressive function of Tr1 cells were found reduced in MS monkeys.
|
19539557 |
2009 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
These results indicate that IL-10 regulatory function is impaired in patients with MS.
|
18200504 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined patterns of Th1/Th2 cytokines (interleukin (IL)-1beta, IL-2, IL-6, IL-12p70, tumor-necrosis factor (TNF)-alpha and interferon-gamma, and IL-4, IL-5 and IL-10, respectively) in the serum of patients with relapsing-remitting MS treated with 250microg interferon-beta 1b or with interferon-beta plus 40mg atorvastatin.
|
18524417 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found elevated expression of interleukin (IL)-23 and IL-10 in untreated MS patients.
|
18424480 |
2008 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution.
|
17481737 |
2007 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were striking defects in the induction of Tr1 cells with CD46 costimulation as measured by IL-10 but not IFN-gamma secretion in patients with MS compared with healthy subjects.
|
17099776 |
2006 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the size of the study group is small, these results indicate that polymorphic variations of two of the major anti-inflammatory cytokines, IL-10 and TGF-beta, may play a role in MS susceptibility.
|
16183136 |
2005 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.
|
15693804 |
2005 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.
|
15693804 |
2005 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results prove a minor role of IL-10 in the autoimmune diabetes risk, although we found the same association trend with IL-10G(*)12 allele as was previously observed for multiple sclerosis and rheumatoid arthritis.
|
15057267 |
2004 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to determine whether sequence variations in the IL-10 gene were associated with MS susceptibility and progression.
|
12101075 |
2003 |